Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs
Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs
Swiss pharma giant Novartis AG (NYSE:NVS) reported a second-quarter adjusted EPS of $1.97, up 21% year over year (+17% on constant currency), beating the consensus of $1.89.
瑞士制药巨头诺华制药股份有限公司（纽交所：NVS）报告第二季度每股收益为1.97美元，同比增长21％（在恒定货币下增长17％），超过了1.89美元的共识预期。
The company's sales reached $12.51 billion, up 11% year over year and 9% in constant currency, beating the consensus of $12.375 billion.
该公司的销售额达到了125.1亿美元，同比增长11％，在恒定货币下增长9％，超过了123.75亿美元的共识预期。
Also Read: FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors.
此外，读：FDA批准诺华Lutathera成为胃肠胰神经内分泌肿瘤儿童患者的首个疗法。
Sales growth is driven by a strong performance from Entresto, Kesimpta, Cosentyx, Kisqali, Leqvio, and Pluvicto.
销售增长源于Entresto，Kesimpta，Cosentyx，Kisqali，Leqvio和Pluvicto的强劲表现。
The volume contributes 15 percentage points to growth. Generic competition had a negative impact of 2 percentage points, and pricing had a negative impact of 2 percentage points.
交易量为增长贡献了15个百分点。通用竞争对手对增长的负面影响为2个百分点，定价影响为2个百分点。
The company reported second-quarter operating income of $4.0 billion, up 43% (+47% at constant currency), mainly driven by higher net sales and lower impairments, partly offset by higher R&D investments.
该公司报告第二季度营业收入为40亿美元，同比增长43％（在恒定货币下为47％），主要受到更高的净销售额和更低的减值影响，部分抵消了更高的研发投资。
Sales of the heart failure drug Entresto reached $1.89 billion, up 25%, and sales of the psoriasis drug Cosentyx increased by 20% to $1.53 billion.
心力衰竭药物Entresto的销售额达到18.9亿美元，同比增长25％，牛皮癣药物Cosentyx的销售额增长20％至15.3亿美元。
Cancer drug Pluvicto, hit by supply crunch, reported sales of $345 million, up 44%.
受供应短缺影响的癌症药物Pluvicto报告销售额34500万美元，同比增长44％。
Sales of Kesimpta for multiple sclerosis increased 63% to $799, sales of the breast cancer drug Kisqali increased 45% to $717 million, and sales of the cholesterol-lowering medication Leqvio generated $182 million, up 133%.
多发性硬化症的Kesimpta的销售额增长63％至799美元，乳腺癌药物Kisqali的销售额增长45％至71700万美元，降低胆固醇的药物Leqvio产生了1.82亿美元的销售额，同比增长133％。
Novartis generated an operating cash flow of $4.90 billion and a free cash flow of $4.60 billion in the second quarter.
诺华制药在第二季度实现营业现金流49亿美元和自由现金流46亿美元。
Guidance: Novartis reaffirms its 2024 net sales growth of high-single to low-double-digit percentage.
指引：诺华制药重申其2024年的净销售额增长为高个位到低双位数百分比。
The company revised its expectations for core operating income, which is now expected to grow in the mid-to-high-teens percentage range, compared to the prior range of low double-digit to mid-teens.
该公司修订了其核心营业收入的预期，预计现在将增长在中到高十几个百分点的范围内，而先前的范围为低双位数到中十几个百分点。
"We remain on track to achieve our mid-term sales growth (+5% cc CAGR 2023-2028) and margin (40%+ by 2027) guidance," commented Vas Narasimhan, CEO.
首席执行官Vas Narasimhan评论道：“我们仍在实现中期销售增长（+5％cc CAGR 2023-2028）和利润率（2027年40％+）的指引目标。”
Price Action: NVS shares are down 3.17% at $108.26 during the premarket session at the last check Thursday.
NV的股票在上周四最后一次检查时在盘前交易中下跌3.17％，报108.26美元。
- Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca.
- 联邦贸易委员会（Federal Trade Commission）针对来自诺和诺德，阿斯利康等公司的糖尿病，减肥，哮喘药物的“垃圾专利清单”。
Photo via Wikimedia Commons
照片通过Wikimedia Commons